Adamson J W
New York Blood Center, NY.
Cancer. 1991 May 15;67(10 Suppl):2708-11. doi: 10.1002/1097-0142(19910515)67:10+<2708::aid-cncr2820671707>3.0.co;2-a.
The development and widespread availability of recombinant products will effect blood centers through reduced product use, replacement of current products, and novel applications of new products. The greatest amount of clinical experience to date has dealt with the use of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia in end-stage renal failure. Data also support its use in anemia associated with acquired immune deficiency syndrome (AIDS), cancer, and chronic inflammatory diseases. This article will focus on the effect of erythropoietin on the demand for erythrocyte use.
重组产品的发展及其广泛可得性将通过减少产品使用、替代现有产品以及新产品的新颖应用对血液中心产生影响。迄今为止，最多的临床经验涉及重组人促红细胞生成素（r-HuEPO）用于治疗终末期肾衰竭贫血。数据也支持其用于与获得性免疫缺陷综合征（AIDS）、癌症及慢性炎症性疾病相关的贫血。本文将聚焦于促红细胞生成素对红细胞使用需求的影响。
